Glucagon 1‐21 reduces intestinal epithelial cell proliferation in parenterally fed rats

Goodlad, R A; Ghatei, M.A.; Bloom, S.R.; Wright, Nicholas

doi:10.1113/expphysiol.1991.sp003556

Cited by 12 publications

(2 citation statements)

References 18 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1988 ) incubated with enteroglucagon. In contrast, studies in vivo failed to show any trophic actions of glucagon on cell proliferation ( Goodlad et al . 1991 ).…”

Section: Discussionmentioning

confidence: 99%

Serotonin and neuroendocrine peptides influence DNA synthesis in rat and human small intestinal cells in vitro

Zachrisson

Uribe

1998

Acta Physiologica Scandinavica

View full text Add to dashboard Cite

Animal studies suggest a mediator role for neuroendocrine peptides and amines in regulating cell proliferation in the gastrointestinal epithelium. Our aim was to examine the effect of serotonin and selected gastrointestinal peptides on DNA synthesis in a rat and human small intestinal cell line in vitro. IEC-6 and FHs-74 cells were incubated with epidermal growth factor (EGF), insulin-like growth factor II, glucagon, substance P, neurokinin A, calcitonin gene-related peptide (GRP, CCGRP), neurotensin and serotonin. The cells were labelled with [methyl-3H] thymidine and processed for autoradiography. DNA synthesis was evaluated by the labelling index. Epidermal growth factor, insulin-like growth factor II, glucagon, and substance P increased the labelling index in a dose-related manner (P < 0.003). In contrast, a significant dose-dependent reduction of the labelling index was observed after administration of serotonin and neurokinin A (P < 0.0001). Neurotensin and CGRP did not affect the labelling index. EGF, insulin-like growth factor II, glucagon, substance P, serotonin and neurokinin A may be important physiological regulators of proliferation, of gastrointestinal cells.

show abstract

“…1988 ) incubated with enteroglucagon. In contrast, studies in vivo failed to show any trophic actions of glucagon on cell proliferation ( Goodlad et al . 1991 ).…”

Section: Discussionmentioning

confidence: 99%

Serotonin and neuroendocrine peptides influence DNA synthesis in rat and human small intestinal cells in vitro

Zachrisson

Uribe

1998

Acta Physiologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…The physiological actions of enteroglucagon remain unclear, as Gregor et al [29] and Goodlad et al [30] reported no trophic effects of enteroglucagon on the small intestine. In the future, this ELISA method for quantifying plasma glicentin levels will make it easier to clarify the role of glicentin in other intestinal diseases or some other postoperative status.…”

Section: Discussionmentioning

confidence: 99%

Plasma Glicentin Concentration in Patients with Crohn's Disease.

Sasaki

Myojo

Tsujikawa

et al. 1998

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Enteroglucagon has been reported to have trophic effects on the intestinal mucosa, and is associated with proliferation and repair after various injuries of the small intestine. Glicentin is an active enteroglucagon, and is present in the largest amount in the intestine. We established a method for quantifying human plasma levels of glicentin, and measured these levels in patients with Crohn's disease. Twenty-three patients with Crohn's disease (14 males and 9 females) and 8 healthy adults were enrolled in this study. A sandwich ELISA method was used to quantify immunoreactive glicentin in plasma sampled from subjects fasting in the early morning and after the oral administration of 75 g glucose (Trelan G(R)®). The plasma glicentin levels in fasting subjects were significantly higher in patients with active-stage Crohn's disease, and were similar between the remission-stage Crohn's disease and normal controls. These levels after glucose administration were significantly higher in patients with active-stage Crohn's disease than in those with the disease in remission or in healthy controls. However, the pattern of the changes in the plasma glicentin levels after the glucose administration was similar among the three groups. These data suggest that plasma glicentin levels might reflect the pathological conditions and activity in Crohn's disease.

show abstract

Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study

Eissele

Göke²,

Weichardt

et al. 1994

Cell Tissue Res

View full text Add to dashboard Cite

The preproglucagon gene encodes, in addition to glucagon, two smaller peptides with structural similarity: glucagon-like peptides 1 and 2. Glucagon-like peptide 1 (GLP-1) 7-36 amide is the most powerful incretin candidate. In the present study, GLP-1 immunoreactivity was investigated in tissue specimens of various types of gastroenteropancreatic tumors, and the serum-levels of GLP-1 were assayed. Immunohistochemical staining of 88 tumors revealed GLP-1 immunoreactivity in 17 neoplasias (19.3%), viz., in 7 out of 33 non-functioning tumors, 4 out of 20 gastrinomas, 4 out of 13 insulinomas, 1 out of 3 vasoactive-intestinal-polypeptide (VIP)omas and 1 adrenocorticotropic-hormone (ACTH)-producing tumor. In these tumors, GLP-1-immunoreactive cells were distributed either diffusely, arranged in clusters, or as single cells. All GLP-1-positive tumors were immunoreactive for glucagon or glicentin, 10 tumors were immunoreactive for pancreatic polypeptide, and 8 tumors for insulin. Ultrastructural analysis of 8 GLP-1-positive tumors, with the immunogold technique, demonstrated GLP-1 immunoreactivity mainly in cells resembling the A-cells of the pancreas or the L-cells of the gut. Of the 17 GLP-1-immunoreactive tumors, 15 were primarily located in the pancreas. Additionally, 2 non-functioning tumors of the rectum were GLP-1 immunoreactive. Five tumors were GLP-1 immunoreactive from 9 patients with multiple endocrine neoplasia I syndrome. Patients with GLP-1-immunoreactive tumors were characterized by a significantly lower rate of distant metastases (P < 0.01) and a higher rate of curative resections (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Glucagon 1‐21 reduces intestinal epithelial cell proliferation in parenterally fed rats

Cited by 12 publications

References 18 publications

Serotonin and neuroendocrine peptides influence DNA synthesis in rat and human small intestinal cells in vitro

Serotonin and neuroendocrine peptides influence DNA synthesis in rat and human small intestinal cells in vitro

Plasma Glicentin Concentration in Patients with Crohn's Disease.

Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study

Contact Info

Product

Resources

About